Dr Reddy's Laboratories has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights for Elyxyb 25 mg/mL to the US-based firm. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults.
Under the terms of the pact, Dr Reddy's will receive $6 million upfront upon closing, followed by $ 9 million one year from closing. Further, it is eligible to receive event-based, sales-based milestones and quarterly earn-out payments.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.70 |
| Dr. Reddys Labs. | 1356.85 |
| Cipla | 1465.15 |
| Zydus Lifesciences | 1112.20 |
| Lupin | 2420.15 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: